The ASCO Post

Older Women With High-Risk Breast Cancer: Addition of Adjuvant Chemotherapy to Hormone Therapy

In the phase III ASTER 70s trial, researchers examined the survival benefit of adding adjuvant chemotherapy to hormone therapy in women aged ≥ 70 years with estrogen receptor–positive, HER2-negative breast cancer with high-risk disease on the basis of genomic grade index.

Subspecialization in Oncology Is Increasing—But Unevenly Distributed Across the Country

Using Medicare claims data, investigators quantified trends in oncologist subspecialization and utilization of subspecialized cancer care in the United States.

Can Baseline PSMA-PET Help to Predict Response to LuPSMA and Enzalutamide in mCRPC?

In a substudy of the Australian phase II ENZA-p trial, baseline PSMA-PET total tumor volume was prognostic for overall survival and predictive for a beneficial effect on overall survival in patients receiving enzalutamide plus LuPSMA for metastatic castration-resistant prostate cancer (mCRPC).

UPMC Hillman Cancer Center Names New Director

An internationally lauded researcher and clinical specialist in hematologic malignancies has been appointed Director of UPMC Hillman Cancer Center, effective November 2025.

Childhood Cancer Survivors and Long-Term Risks for Health Conditions: New Data

A research team conducted the first-ever study of childhood cancer survivors who reach the age of 50—a growing population—to determine their incidence of new cancers and chronic health conditions.

Best of ASCO 20th Anniversary: Advancing Medicine and Patient Care, ASCO Style!

"The Best of ASCO meetings have become very popular and are being held annually in more than 35 countries in Europe, Asia, Africa, and South America..., and [they offer] the chance for people who were unable to attend ASCO meetings to discuss study findings as they were presented [there]."